Analyst Ratings For Cara Therapeutics
Portfolio Pulse from Benzinga Insights
Cara Therapeutics (NASDAQ:CARA) has been analyzed by 5 analysts in the last three months, showing a range of bullish to bearish perspectives. The average 12-month price target is $4.72, with a high of $5.00 and a low of $3.60. The company's market capitalization is strong, but it faces challenges with revenue growth, net margin, ROE, and ROA.
June 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cara Therapeutics has received mixed analyst ratings with an average price target of $4.72. The company faces challenges in revenue growth, net margin, ROE, and ROA, despite a strong market capitalization.
The mixed analyst ratings and the average price target of $4.72 suggest a neutral short-term impact on the stock price. The company's strong market capitalization is a positive, but significant challenges in revenue growth, net margin, ROE, and ROA could offset this, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100